RT Journal Article
SR Electronic
T1 Role of Surgical Treatment in Breast Cancer Liver Metastases: A Single Center Experience
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 5563
OP 5568
VO 34
IS 10
A1 BACALBASA, NICOLAE
A1 DIMA, SIMONA OLIMPIA
A1 PURTAN-PURNICHESCU, RALUCA
A1 HERLEA, VLAD
A1 POPESCU, IRINEL
YR 2014
UL http://ar.iiarjournals.org/content/34/10/5563.abstract
AB Background/Aim: The aim of the present study was to review a single hepatobiliary center experience, the benefit of hepatic metastasectomy in breast cancer liver metastases (BCLM) patients and to identify predictors of survival. Patients and Methods: Fifty-two female patients underwent surgery for BCLM between 2002 and 2013. Only patients with liver resections (n=43) were included in the analysis. Results: The median survival of the 43 patients with liver resection was 32.2 months. The factors significantly associated with overall post-hepatectomy survival were estrogen/progesteron receptor (ER/PR) status (p=0.002), node involvement of the primary tumor (p=0.049), size (p=0.005) and number (p=0.006) of the metastatic lesions. The 1-, 3- and 5-year survival rates after curative liver resection were 93.02%, 74.42%, 58.14%, respectively. Conclusion: BCLM resection is a safe procedure and offers survival benefit, especially in patients with reduced liver metastatic burden (solitary metastases, diameter of the metastases <5 cm) and positive ER/PR status.